The average one-year price target for Lipocine (NasdaqCM:LPCN) has been revised to $13.26 / share. This is an increase of 19.54% from the prior estimate of $11.09 dated February 21, 2026.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $11.11 to a high of $15.75 / share. The average price target represents an increase of 79.19% from the latest reported closing price of $7.40 / share.
What is the Fund Sentiment?
There are 26 funds or institutions reporting positions in Lipocine. This is an decrease of 11 owner(s) or 29.73% in the last quarter. Average portfolio weight of all funds dedicated to LPCN is 0.11%, an increase of 114,823.43%. Total shares owned by institutions increased in the last three months by 198.97% to 1,630K shares.
What are Other Shareholders Doing?
Squadron Capital Management holds 530K shares representing 7.26% ownership of the company.
Diadema Partners holds 261K shares representing 3.57% ownership of the company.
Ikarian Capital holds 200K shares representing 2.73% ownership of the company.
Persistent Asset Partners holds 71K shares representing 0.97% ownership of the company.
Geode Capital Management holds 62K shares representing 0.86% ownership of the company. In its prior filing, the firm reported owning 61K shares , representing an increase of 2.20%. The firm increased its portfolio allocation in LPCN by 177.72% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
